Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow LGVN by emailGet an email when LGVN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LGVN, unsubscribe in one click. Privacy
📣 What LGVN Says Is Next
in 2027 · “The Company currently anticipates initiation of the Phase 2 clinical trial in 2027, with planning and preparation beginning in 2026.”
Company press release, Aug 12, 2026 · SEC filing
fourth quarter of 2026 · “The net proceeds from the initial tranche of the financing are expected to fund the Company’s current operating plans into the fourth quarter of 2026, past the anticipated pivotal Phase 2b ELPIS II clinical trial 3Q26 topline data readout.”
Company press release, Mar 12, 2026 · SEC filing
in 2026 · “The Company currently anticipates initiation of the pivotal Phase 2 clinical trial in 2026, subject to obtaining necessary financing.”
Company press release, Nov 4, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full LGVN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LGVN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.